Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25759211 | 0.85 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL26960329 | 0.82 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25692779 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25693224 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13989748 | 0.79 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25693049 | 0.79 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL137308 | 0.75 | LMNA (0.65) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL28564954 | 0.74 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5213739 | 0.74 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL7768532 | 0.73 | ALDH1A1 (0.56) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11773061-B2 | Cyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773061-B2 | Cyclic lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | NPC1 90/4885RAB9A 1562/4885SMN1; SMN2 2719/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | NPC1 73/4885RAB9A 1504/4885SMN1; SMN2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.